Hyoscine N-butylbromide for preventing propofol injection pai

Completed

• Conditions: propofol injection pain; Anaesthesiology - Anaesthetics

• Registration Number: ACTRN12616000142437
• Lead Sponsor: Konya Training and Research Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-02-05
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

ASA physical status I and II, scheduled to undergo routine outpatient surgery under general anesthesia

Exclusion Criteria

An allergy to the study drugs, end-stage renal disease, pregnancy, patients taking sedatives or analgesics, patients requiring a rapid sequence induction and intubation, refusal to participate, and patients with a neurological or cardiovascular disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Assessment of Hyoscine N-butylbromide prevention on propofol injection pain [ Injection pain severity was assessed using the following four-point pain response scale: 0 = no pain; 1 = mild pain (pain reported only in response to questioning and without behavioral signs); 2 = moderate pain (pain reported in response to questioning and accompanied by a behavioral sign, or pain reported spontaneously without questioning); and 3 = severe pain (strong vocal response or response accompanied by facial grimacing, arm withdrawal, or tears).][Ten seconds following the injection of propofol, propofol injection pain will be evaluated.]

Secondary Outcome Measures

Name	Time	Method
non[non]